Treatment of the lennox syndrome with ACTH: A clinical and electroencephalographic study

Yamatogi, Yasuko; Ohtsuka, Yoko; Ishida, Takashi; Ichiba, N; Ishida, Sumio; Miyake, Susumu; Oka, Eiji; Ohtahara, Shunsuke

doi:10.1016/s0387-7604(79)80041-8

Cited by 81 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, there have been few reports of steroid use in childhood epilepsy after the first year of life. Some benefits have been previously reported with ACTH (Yamatogi et al 1979) and corticosteroids (Roger et al 1989) in patients with LGS.…”

Section: Chronic Medical Treatmentmentioning

confidence: 92%

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Rijckevorsel¹

2008

NDT

118

View full text Add to dashboard Cite

Lennox-Gastaut syndrome (LGS) is a rare, age-related syndrome, characterized by multiple seizure types, a specifi c electro-encephalographic pattern, and mental regression. However, published data on the etiology, evolution, and therapeutic approach of LGS are contradictory, partly because the precise defi nition of LGS used in the literature varies. In the most recent classifi cation, LGS belongs to the epileptic encephalopathies and is highly refractory to all antiepileptic drugs. Numerous treatments, medical and non-medical, have been proposed and results mostly from open studies or case series have been published. Sometimes, patients with LGS are included in a more global group of patients with refractory epilepsy. Only 6 randomized double-blind controlled trials of medical treatments, which included patients with LGS, have been published. Overall, treatment is rarely effective and the fi nal prognosis remains poor in spite of new therapeutic strategies. Co-morbidities need specifi c treatment. This paper summarizes the defi nition, diagnosis and therapeutic approach to LGS, including not only recognized antiepileptic drugs, but also "off label" medications, immune therapy, diet, surgery and some perspectives for the future.

show abstract

Section: Chronic Medical Treatmentmentioning

confidence: 92%

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Rijckevorsel¹

2008

NDT

118

View full text Add to dashboard Cite

show abstract

“…17,19,22e26 In the study of Yamatogi et al improvement of the EEG registration reflected a decrease in the seizure frequency. 19 Duration of treatment varied considerably, as some authors based their decision to continue treatment on the initial effectiveness and side effects after two weeks of treatment. In the study of Kramer et al ACTH was superior to prednisone with good response in respectively 92% and 35% of the children.…”

Section: 2mentioning

confidence: 99%

Effectiveness of a hybrid corticosteroid treatment regimen on refractory childhood seizures and a review of other corticosteroid treatments

Bakker

Catsman‐Berrevoets

Neuteboom

2015

European Journal of Paediatric Neurology

View full text Add to dashboard Cite

“…It has been shown that ACTH had superior efficacy in the cessation of spasms, improved developmental prognosis, and normalization of electroencephalography (EEG; Snead et al, 1983; Baram et al, 1996; Kivity et al, 2004). In the treatment of refractory epileptic encephalopathies, such as West syndrome, Ohtahara syndrome, Dravet syndrome, Lennox-Gastaut syndrome, Landau-Kleffner syndrome, epilepsy with continuous spike waves during slow-wave sleep and drug-resistant myoclonic atonic epilepsy, a significant proportion of ACTH- and steroid-treated pediatric patients were reported to be seizure-free for an extended period of time, albeit relapsed over time (Yamatogi et al, 1979; Snead et al, 1983; Donat, 1992; Engel, 2001). …”

Section: Clinical Evidence Of the Involvement Of Immune Responses In mentioning

confidence: 99%

Immune mechanisms in epileptogenesis

Miller

Koh

2013

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Epilepsy is a chronic brain disorder that affects 1% of the human population worldwide. Immune responses are implicated in seizure induction and the development of epilepsy. Pre-clinical and clinical evidence have accumulated to suggest a positive feedback cycle between brain inflammation and epileptogenesis. Prolonged or recurrent seizures and brain injuries lead to upregulation of proinflammatory cytokines and activated immune responses to further increase seizure susceptibility, promote neuronal excitability, and induce blood–brain barrier breakdown. This review focuses on the potential role of innate and adaptive immune responses in the pathogenesis of epilepsy. Both human studies and animal models that help delineate the contributions of brain inflammation in epileptogenesis will be discussed. We highlight the critical role of brain-resident immune mediators and emphasize the contribution of brain-infiltrating peripheral leukocytes. Additionally, we propose possible immune mechanisms that underlie epileptogenesis. Several proinflammatory pathways are discussed, including the interleukin-1 receptor/toll-like receptor signaling cascade, the pathways activated by damage-associated molecular patterns, and the cyclooxygenase-2/prostaglandin pathway. Finally, development of better therapies that target the key constituents and processes identified in these mechanisms are considered, for instance, engineering antagonizing agents that effectively block these pathways in an antigen-specific manner.

show abstract

Treatment of the lennox syndrome with ACTH: A clinical and electroencephalographic study

Cited by 81 publications

References 5 publications

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Treatment of Lennox-Gastaut syndrome: overview and recent findings

Effectiveness of a hybrid corticosteroid treatment regimen on refractory childhood seizures and a review of other corticosteroid treatments

Immune mechanisms in epileptogenesis

Contact Info

Product

Resources

About